Ascendis Pharma, Inc.

146 articles with Ascendis Pharma, Inc.

• Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference

  2/18/2021

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate at the SVB Leerink 10th Annual Global Healthcare Conference.

• Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference

  1/11/2021

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the company’s 2021 key milestones at the 39th Annual J.P. Morgan Healthcare Conference.

• Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

  12/30/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate the clinical program of TransCon TLR7/8 Agonist.

• Ascendis Pharma A/S Announces Planned Board Transition

  12/14/2020

  – Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM – COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 A

• Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

  11/25/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate in the Evercore ISI 3 rd Annual HealthCONx Virtual Conference on December 3, 2020. Company executives will provide a business overview and update on the company’s pipeline programs. Details Event Everc

• Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20

  11/11/2020

  – Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –

• Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results

  11/11/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the quarter ended September 30, 2020.

• Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases

  11/3/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases.   

• Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11

  11/2/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, November 11, 2020 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2020 financial results and provide a business update.

• Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences

  10/21/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced five presentations featuring the company’s endocrinology rare disease programs at two upcoming medical conferences: European Calcified Tissue Society (ECTS) 2020, taking place online October 22–24, 2020, and the Pediatric Endocrinology Nursing Society (PENS) national conference,

• Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypoparathyroidism

  9/28/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced preliminary six-month results from the open-label extension (OLE) portion of PaTH Forward, a global phase 2 trial evaluating the safety,

• Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan

  9/23/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has filed a Clinical Trial Notification (CTN) with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate the company’s phase 3 riGHt Trial of TransCon™ hGH (lonapegsomatropin), a long-acting prodrug of somatropin (hGH), for the treatment for pediatri

• Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020

  9/15/2020

  – Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –       –  Public encouraged to visit www.together4growth.com and share their growth disorder stories using #Together4Growth – COPENHAGEN, Denmark, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative technologies to address unmet medica

• Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

  9/11/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference in September.

• Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting

  9/10/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced three presentations for its TransCon PTH program for hypoparathyroidism (HP) at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event, taking place September 11–15.  In addition, results from the randomized, double-blind phase 2 PaTH Forw

• Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

  9/8/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical needs, announced today the submission of a MAA to the EMA seeking approval for TransCon hGH (lonapegsomatropin), an investigational long-acting once-weekly prodrug of somatropin (human growth hormone or hGH), for the treatment of pediatric patients who are diagnosed with growth hormone deficiency (GHD).

• Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)

  9/4/2020

  – Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2021 – – FDA indicated that it is currently not planning to hold an Advisory Committee Meeting –

• Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology

  9/4/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, announced two presentations for its TransCon PTH program in adult hypoparathyroidism at the 22nd European Congress of Endocrinology 2020, taking place online September 5–9, 2020.

• Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference

  9/2/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will participate in the 2020 Wells Fargo Virtual Healthcare Conference in September.

• Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial

  8/27/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced new data from PaTH Forward and financial results for the quarter ended June 30, 2020.